Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
RegulatoryapprovedNerandomilastJascaydPositive
AI Analysis
Summary
Nerandomilast (Jascayd) has been approved by the MHRA for treating adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis. The MHRA will continue to monitor the safety and effectiveness of the product post-approval.
Outcome Details
MHRA approval for nerandomilast (Jascayd) in adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Importance:8/10
Sentiment:
0.80
regulatory approvalMHRApulmonary fibrosisUK
Read the original article
Published by MHRA (UK) on July 8, 2026 10:15 AM